Journal ArticleDOI
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
Chikashi Nakanishi,Masakazu Toi +1 more
TLDR
The cytotoxicity of chemotherapeutic agents is attributed to apoptosis, and there is evidence that inhibitors of NF-κB might promote apoptosis in cancer cells and can NF-σB inhibitors be used to overcome resistance to chemotherAPEutic agents.Abstract:
The cytotoxicity of chemotherapeutic agents is attributed to apoptosis. Acquired resistance to the effects of chemotherapy has emerged as a significant impediment to effective cancer therapy. One feature that cytotoxic treatments of cancer have in common is their activation of the transcription factor nuclear factor-kappaB (NF-kappaB), which regulates cell survival. NF-kappaB activation suppresses the apoptotic potential of chemotherapeutic agents and contributes to resistance. What evidence is there that inhibitors of NF-kappaB might promote apoptosis in cancer cells and can NF-kappaB inhibitors be used to overcome resistance to chemotherapeutic agents?read more
Citations
More filters
Journal ArticleDOI
Molecular mechanisms of necroptosis: an ordered cellular explosion.
TL;DR: Evidence now reveals that necrosis can also occur in a regulated manner, and necroptosis participates in the pathogenesis of diseases, including ischaemic injury, neurodegeneration and viral infection, thereby representing an attractive target for the avoidance of unwarranted cell death.
Journal ArticleDOI
Inflammation meets cancer, with NF-κB as the matchmaker
Yinon Ben-Neriah,Michael Karin +1 more
TL;DR: Although it seems to fulfill a distinctly tumor-promoting role in many types of cancer, NF-κB has a confounding role in certain tumors.
Journal ArticleDOI
Is NF-κB a good target for cancer therapy? Hopes and pitfalls
Véronique Baud,Michael Karin +1 more
TL;DR: Recent evidence from cancer genetics and cancer genome studies that support the involvement of NF-κB in human cancer, particularly in multiple myeloma are discussed.
Journal ArticleDOI
Strategies to improve radiotherapy with targeted drugs
TL;DR: Improved understanding of the molecular response of cells and tissues to ionizing radiation and a new appreciation of the exploitable genetic alterations in tumours have led to the development of treatments combining pharmacological interventions with ionizing Radiation that more specifically target either tumour or normal tissue, leading to improvements in efficacy.
Journal ArticleDOI
Discovery and Development of the G-rich Oligonucleotide AS1411 as a Novel Treatment for Cancer
TL;DR: The serendipitous discovery of the G-rich oligonucleotides led to the identification of nucleolin as a new molecular target for cancer therapy, and this molecule functions as an aptamer to nucleolin, a multifunctional protein that is highly expressed by cancer cells, both intracellularly and on the cell surface.
References
More filters
Journal ArticleDOI
Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.
Michael Karin,Yinon Ben-Neriah +1 more
TL;DR: Recent progress has been made in understanding the details of the signaling pathways that regulate NF-kappaB activity, particularly those responding to the proinflammatory cytokines tumor necrosis factor-alpha and interleukin-1.
Journal ArticleDOI
Signaling to NF-kappaB.
Matthew S. Hayden,Sankar Ghosh +1 more
TL;DR: An overview of established NF-kappaB signaling pathways is provided with focus on the current state of research into the mechanisms that regulate IKK activation and NF- kappaB transcriptional activity.
Journal ArticleDOI
TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB
TL;DR: The activation of the transcription factor nuclear factor-kappa B by tumor necrosis factor, ionizing radiation, or daunorubicin, was found to protect from cell killing, providing a mechanism of cellular resistance to killing by some apoptotic reagents.
Journal ArticleDOI
IAP family proteins—suppressors of apoptosis
Quinn Deveraux,John C. Reed +1 more
TL;DR: Although the mechanism used by the IAPs to suppress cell death remains debated, several studies have provided insights into the biochemical functions of these intriguing proteins and a variety of reports have suggested an important role for the I APs in some human diseases.
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.